Leap Therapeutics (LPTX) Competitors $0.37 +0.01 (+2.30%) Closing price 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.99%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, ABVC, ALGS, UNCY, ANL, RENB, KRON, VTVT, ATNM, and PDSBShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), ABVC BioPharma (ABVC), Aligos Therapeutics (ALGS), Unicycive Therapeutics (UNCY), Adlai Nortye (ANL), Renovaro (RENB), Kronos Bio (KRON), vTv Therapeutics (VTVT), Actinium Pharmaceuticals (ATNM), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences ABVC BioPharma Aligos Therapeutics Unicycive Therapeutics Adlai Nortye Renovaro Kronos Bio vTv Therapeutics Actinium Pharmaceuticals PDS Biotechnology Leap Therapeutics (NASDAQ:LPTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Which has stronger earnings and valuation, LPTX or DTIL? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.70-0.21Precision BioSciences$68.70M0.81$7.17M-$2.01-2.49 Do insiders & institutionals hold more shares of LPTX or DTIL? 30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 7.5% of Leap Therapeutics shares are held by company insiders. Comparatively, 4.5% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer LPTX or DTIL? In the previous week, Precision BioSciences had 2 more articles in the media than Leap Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.67 beat Precision BioSciences' score of 0.29 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Leap Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LPTX or DTIL? Leap Therapeutics presently has a consensus target price of $3.38, suggesting a potential upside of 823.65%. Precision BioSciences has a consensus target price of $47.00, suggesting a potential upside of 840.00%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LPTX or DTIL more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -162.15% -120.05% Precision BioSciences -42.99%-69.26%-29.30% Which has more volatility and risk, LPTX or DTIL? Leap Therapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. SummaryPrecision BioSciences beats Leap Therapeutics on 10 of the 14 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.80M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-0.2120.8627.9419.95Price / SalesN/A246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book0.408.308.635.82Net Income-$67.56M-$55.19M$3.24B$258.42M7 Day Performance7.16%5.07%3.22%1.94%1 Month Performance30.45%17.61%10.72%12.02%1 Year Performance-82.68%7.03%34.94%20.80% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics1.9494 of 5 stars$0.37+2.3%$3.38+823.6%-84.1%$14.80MN/A-0.2140DTILPrecision BioSciences4.1551 of 5 stars$4.65+0.9%$47.00+910.8%-50.4%$51.12M$68.70M-2.31200Upcoming EarningsABVCABVC BioPharma0.6761 of 5 stars$3.52+5.1%N/A+287.6%$56.89M$510K-27.0830ALGSAligos Therapeutics3.7921 of 5 stars$8.64-5.7%$70.00+710.2%-32.5%$56.01M$3.94M-0.4990News CoverageGap DownUNCYUnicycive Therapeutics3.0258 of 5 stars$4.50+1.6%$60.00+1,233.3%+15.8%$56M$680K-0.889ANLAdlai Nortye1.4037 of 5 stars$1.52+1.3%$9.00+492.1%-58.4%$55.35M$5M0.00127Positive NewsGap DownRENBRenovaro2.2102 of 5 stars$0.31-2.8%N/A-74.4%$54.54MN/A-0.4020News CoverageGap DownKRONKronos BioN/A$0.88+1.5%$1.63+84.7%-35.8%$53.72M$9.85M-0.82100VTVTvTv Therapeutics1.5991 of 5 stars$16.55+2.4%$35.50+114.5%-31.7%$53.57M$1.02M-5.509Positive NewsATNMActinium Pharmaceuticals2.7438 of 5 stars$1.69-1.2%$4.00+136.7%N/A$52.72MN/A-1.2230News CoveragePDSBPDS Biotechnology1.029 of 5 stars$1.15flat$9.00+682.6%-70.4%$52.57MN/A-1.2220 Related Companies and Tools Related Companies Precision BioSciences Alternatives ABVC BioPharma Alternatives Aligos Therapeutics Alternatives Unicycive Therapeutics Alternatives Adlai Nortye Alternatives Renovaro Alternatives Kronos Bio Alternatives vTv Therapeutics Alternatives Actinium Pharmaceuticals Alternatives PDS Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
